You are viewing the site in preview mode
Skip to main content
| |
Methotrexate
|
Leflunomide
|
|---|
|
Yes n*(%)
|
PRˆ (IC95%)
|
p‡
|
Yes n*(%)
|
PRˆ (IC95%)
|
p‡
|
|---|
|
Cardiovascular Comorbidities
|
Yes
|
463 (62.4)
|
0.945 (0.862–1.036)
|
0.232
|
251 (66.4)
|
1.068 (0.975–1.170)
|
0.167
|
|
No
|
279 (37.6)
|
1.107 (0.935–1.311)
|
127 (33.6)
|
0.889 (0.750–1.053)
|
|
Systemic Arterial Hypertension
|
Yes
|
365 (49.2)
|
0.958 (0.847–1.083)
|
0.499
|
195 (51.6)
|
1.052 (0.931–1.188)
|
0.423
|
|
No
|
377 (50.8)
|
1.044 (0.921–1.184)
|
183 (48.4)
|
0.950 (0.838–1.078)
|
|
Dyslipidemia
|
Yes
|
236 (31.8)
|
0.937 (0.785–1.117)
|
0.469
|
129 (34.1)
|
1.076 (0.903–1.283)
|
0.414
|
|
No
|
506 (68.2)
|
1.033 (0.946–1.127)
|
249 (65.9)
|
0.965 (0.884–1.053)
|
|
Diabetes Mellitus
|
Yes
|
111 (15)
|
1.017 (0.755–1.371)
|
0.910
|
52 (13.8)
|
0.891 (0.657–1.207)
|
0.453
|
|
No
|
631 (85)
|
0.997 (0.947–1.050)
|
326 (86.2)
|
1.020 (0.970–1.073)
|
|
Congestive Heart Failure
|
Yes
|
18 (2.4)
|
1.512 (0.605–3.777)
|
0.372
|
7 (1.9)
|
0.804 (0.336–1.922)
|
0.623
|
|
No
|
724 (97.6)
|
0.992 (0.975–1.009)
|
371 (98.1)
|
1.005 (0.987–1.023)
|
|
Cerebrovascular Disease
|
Yes
|
14 (1.9)
|
0.706 (0.316–1.574)
|
0.392
|
9 (2.4)
|
1.171 (0.517–2.652)
|
0.704
|
|
No
|
728 (98.1)
|
1.008 (0.989–1.028)
|
369 (97.6)
|
0.996 (0.978–1.015)
|
|
Acute Myocardial Infarction
|
Yes
|
12 (1.6)
|
1.210 (0.429–3.408)
|
0.718
|
3 (0.8)
|
0.418 (0.121–1.447)
|
0.200
|
|
No
|
730 (98.4)
|
0.997 (0.982–1.012)
|
375 (99.2)
|
1.011 (0.998–1.025)
|
|
Peripheral Vascular Disease
|
Yes
|
5 (0.7)
|
0.840 (0.202–3.496)
|
1.000
|
5 (1.3)
|
3.254 (0.782–13.543)
|
0.129
|
|
No
|
737 (99.3)
|
1.001 (0.990–1.012)
|
373 (98.7)
|
0.991 (0.970–1.003)
|
- *Absolute frequencies; ˆ Prevalence Ratio ‡ Significance level
